Peringkat dalam Saham
#41904
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition,... Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Harga Saham
$0.0001
Terakhir disinkronkan: 2026-08-11
Kapitalisasi Pasar
$7.87K
Perubahan (1 tahun)
-50.00%
Perdagangan Biostax Corp. (BTAX)
Pendapatan untuk Biostax Corp. (BTAX)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Biostax Corp., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Biostax Corp. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan |
Pendapatan |
Perbedaan Pendapatan |
Negara |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
$10.11B |
-
|
BE
|
|
|
- |
-
|
KR
|
